Myasthenia Gravis - Drug Pipeline Landscape, 2023
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement.
Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be used for diagnosis.
Myasthenia gravis treatments include medications, monoclonal antibodies, iv immunoglobulin (ivig), plasma exchange (plasmapheresis) and surgery.
The companies active in development of Myasthenia Gravis Drugs are Ahead Therapeutics, Alexion Pharmaceuticals, AnTolRx, Argenx, Cabaletta Bio etc.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Myasthenia Gravis treatment such as Efgartigimod IV, amifampridine, batoclimab and others. Key players involved in the development of therapies to treat Myasthenia gravis are Alexion Pharmaceuticals, argenx, UCB Biopharma and others. One drug is in Pre-Registration, 10+ drugs are in Phase III and 6 drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0, preclinical, discovery and unknown stages of development. In Sep 2022, argenx SE submitted Biologics License Application (BLA) to the U.S. FDA for SC efgartigimod. In Nov 2022, UCB announced that US FDA has accepted to review the NDA for zilucoplan.
Global Insight Service's, Myasthenia Gravis - Drug Pipeline Landscape, 2023 report provides an overview of the Myasthenia gravis pipeline drugs. This report covers detailed insights on Myasthenia Gravis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Myasthenia Gravis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
To plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook